Overcoming obstacles to repurposing for neurodegenerative disease. Shineman, D. W., Alam, J., Anderson, M., Black, S. E., Carman, A. J., Cummings, J. L., Dacks, P. A., Dudley, J. T., Frail, D. E., Green, A., Lane, R. F., Lappin, D., Simuni, T., Stefanacci, R. G., Sherer, T., & Fillit, H. M. Annals of Clinical and Translational Neurology, 1(7):512–518, July, 2014. ![Overcoming obstacles to repurposing for neurodegenerative disease [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex Repurposing Food and Drug Administration (FDA)-approved drugs for a new indication may offer an accelerated pathway for new treatments to patients but is also fraught with significant commercial, regulatory, and reimbursement challenges. The Alzheimer’s Drug Discovery Foundation (ADDF) and the Michael J. Fox Foundation for Parkinson’s Research (MJFF) convened an advisory panel in October 2013 to understand stakeholder perspectives related to repurposing FDA-approved drugs for neurodegenerative diseases. Here, we present opportunities on how philanthropy, industry, and government can begin to address these challenges, promote policy changes, and develop targeted funding strategies to accelerate the potential of FDA-approved repurposed drugs.
@article{shineman_overcoming_2014-1,
title = {Overcoming obstacles to repurposing for neurodegenerative disease},
volume = {1},
issn = {23289503},
url = {http://doi.wiley.com/10.1002/acn3.76},
doi = {10.1002/acn3.76},
abstract = {Repurposing Food and Drug Administration (FDA)-approved drugs for a new indication may offer an accelerated pathway for new treatments to patients but is also fraught with significant commercial, regulatory, and reimbursement challenges. The Alzheimer’s Drug Discovery Foundation (ADDF) and the Michael J. Fox Foundation for Parkinson’s Research (MJFF) convened an advisory panel in October 2013 to understand stakeholder perspectives related to repurposing FDA-approved drugs for neurodegenerative diseases. Here, we present opportunities on how philanthropy, industry, and government can begin to address these challenges, promote policy changes, and develop targeted funding strategies to accelerate the potential of FDA-approved repurposed drugs.},
language = {en},
number = {7},
urldate = {2019-05-02},
journal = {Annals of Clinical and Translational Neurology},
author = {Shineman, Diana W. and Alam, John and Anderson, Margaret and Black, Sandra E. and Carman, Aaron J. and Cummings, Jeffrey L. and Dacks, Penny A. and Dudley, Joel T. and Frail, Donald E. and Green, Allan and Lane, Rachel F. and Lappin, Debra and Simuni, Tanya and Stefanacci, Richard G. and Sherer, Todd and Fillit, Howard M.},
month = jul,
year = {2014},
pages = {512--518},
file = {Shineman et al. - 2014 - Overcoming obstacles to repurposing for neurodegen.pdf:/Users/neil.hawkins/Zotero/storage/6VVHANLA/Shineman et al. - 2014 - Overcoming obstacles to repurposing for neurodegen.pdf:application/pdf},
}
Downloads: 0
{"_id":"uH77AL8t6fYsHCm2o","bibbaseid":"shineman-alam-anderson-black-carman-cummings-dacks-dudley-etal-overcomingobstaclestorepurposingforneurodegenerativedisease-2014","author_short":["Shineman, D. W.","Alam, J.","Anderson, M.","Black, S. E.","Carman, A. J.","Cummings, J. L.","Dacks, P. A.","Dudley, J. T.","Frail, D. E.","Green, A.","Lane, R. F.","Lappin, D.","Simuni, T.","Stefanacci, R. G.","Sherer, T.","Fillit, H. M."],"bibdata":{"bibtype":"article","type":"article","title":"Overcoming obstacles to repurposing for neurodegenerative disease","volume":"1","issn":"23289503","url":"http://doi.wiley.com/10.1002/acn3.76","doi":"10.1002/acn3.76","abstract":"Repurposing Food and Drug Administration (FDA)-approved drugs for a new indication may offer an accelerated pathway for new treatments to patients but is also fraught with significant commercial, regulatory, and reimbursement challenges. The Alzheimer’s Drug Discovery Foundation (ADDF) and the Michael J. Fox Foundation for Parkinson’s Research (MJFF) convened an advisory panel in October 2013 to understand stakeholder perspectives related to repurposing FDA-approved drugs for neurodegenerative diseases. Here, we present opportunities on how philanthropy, industry, and government can begin to address these challenges, promote policy changes, and develop targeted funding strategies to accelerate the potential of FDA-approved repurposed drugs.","language":"en","number":"7","urldate":"2019-05-02","journal":"Annals of Clinical and Translational Neurology","author":[{"propositions":[],"lastnames":["Shineman"],"firstnames":["Diana","W."],"suffixes":[]},{"propositions":[],"lastnames":["Alam"],"firstnames":["John"],"suffixes":[]},{"propositions":[],"lastnames":["Anderson"],"firstnames":["Margaret"],"suffixes":[]},{"propositions":[],"lastnames":["Black"],"firstnames":["Sandra","E."],"suffixes":[]},{"propositions":[],"lastnames":["Carman"],"firstnames":["Aaron","J."],"suffixes":[]},{"propositions":[],"lastnames":["Cummings"],"firstnames":["Jeffrey","L."],"suffixes":[]},{"propositions":[],"lastnames":["Dacks"],"firstnames":["Penny","A."],"suffixes":[]},{"propositions":[],"lastnames":["Dudley"],"firstnames":["Joel","T."],"suffixes":[]},{"propositions":[],"lastnames":["Frail"],"firstnames":["Donald","E."],"suffixes":[]},{"propositions":[],"lastnames":["Green"],"firstnames":["Allan"],"suffixes":[]},{"propositions":[],"lastnames":["Lane"],"firstnames":["Rachel","F."],"suffixes":[]},{"propositions":[],"lastnames":["Lappin"],"firstnames":["Debra"],"suffixes":[]},{"propositions":[],"lastnames":["Simuni"],"firstnames":["Tanya"],"suffixes":[]},{"propositions":[],"lastnames":["Stefanacci"],"firstnames":["Richard","G."],"suffixes":[]},{"propositions":[],"lastnames":["Sherer"],"firstnames":["Todd"],"suffixes":[]},{"propositions":[],"lastnames":["Fillit"],"firstnames":["Howard","M."],"suffixes":[]}],"month":"July","year":"2014","pages":"512–518","file":"Shineman et al. - 2014 - Overcoming obstacles to repurposing for neurodegen.pdf:/Users/neil.hawkins/Zotero/storage/6VVHANLA/Shineman et al. - 2014 - Overcoming obstacles to repurposing for neurodegen.pdf:application/pdf","bibtex":"@article{shineman_overcoming_2014-1,\n\ttitle = {Overcoming obstacles to repurposing for neurodegenerative disease},\n\tvolume = {1},\n\tissn = {23289503},\n\turl = {http://doi.wiley.com/10.1002/acn3.76},\n\tdoi = {10.1002/acn3.76},\n\tabstract = {Repurposing Food and Drug Administration (FDA)-approved drugs for a new indication may offer an accelerated pathway for new treatments to patients but is also fraught with significant commercial, regulatory, and reimbursement challenges. The Alzheimer’s Drug Discovery Foundation (ADDF) and the Michael J. Fox Foundation for Parkinson’s Research (MJFF) convened an advisory panel in October 2013 to understand stakeholder perspectives related to repurposing FDA-approved drugs for neurodegenerative diseases. Here, we present opportunities on how philanthropy, industry, and government can begin to address these challenges, promote policy changes, and develop targeted funding strategies to accelerate the potential of FDA-approved repurposed drugs.},\n\tlanguage = {en},\n\tnumber = {7},\n\turldate = {2019-05-02},\n\tjournal = {Annals of Clinical and Translational Neurology},\n\tauthor = {Shineman, Diana W. and Alam, John and Anderson, Margaret and Black, Sandra E. and Carman, Aaron J. and Cummings, Jeffrey L. and Dacks, Penny A. and Dudley, Joel T. and Frail, Donald E. and Green, Allan and Lane, Rachel F. and Lappin, Debra and Simuni, Tanya and Stefanacci, Richard G. and Sherer, Todd and Fillit, Howard M.},\n\tmonth = jul,\n\tyear = {2014},\n\tpages = {512--518},\n\tfile = {Shineman et al. - 2014 - Overcoming obstacles to repurposing for neurodegen.pdf:/Users/neil.hawkins/Zotero/storage/6VVHANLA/Shineman et al. - 2014 - Overcoming obstacles to repurposing for neurodegen.pdf:application/pdf},\n}\n\n","author_short":["Shineman, D. W.","Alam, J.","Anderson, M.","Black, S. E.","Carman, A. J.","Cummings, J. L.","Dacks, P. A.","Dudley, J. T.","Frail, D. E.","Green, A.","Lane, R. F.","Lappin, D.","Simuni, T.","Stefanacci, R. G.","Sherer, T.","Fillit, H. M."],"bibbaseid":"shineman-alam-anderson-black-carman-cummings-dacks-dudley-etal-overcomingobstaclestorepurposingforneurodegenerativedisease-2014","role":"author","urls":{"Paper":"http://doi.wiley.com/10.1002/acn3.76"},"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://bibbase.org/f/FfNE7kWA6pCvwcJZF/myPubs.bib","dataSources":["ZaHtWavQhcwZqKLNF","iRRNaRs6FkffgErta","v8uQmZsBpiqycmskv"],"keywords":[],"search_terms":["overcoming","obstacles","repurposing","neurodegenerative","disease","shineman","alam","anderson","black","carman","cummings","dacks","dudley","frail","green","lane","lappin","simuni","stefanacci","sherer","fillit"],"title":"Overcoming obstacles to repurposing for neurodegenerative disease","year":2014}